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1. Introduction 
Hepatocellular carcinoma (HCC) is the sixth most common type of cancer in the world, with 
approximately 630,000 new cases each year (Alves et al., 2011). It is also the third most 
common cause of cancer related mortality (Parkin et al., 2005). Moreover, the incidence of 
HCC has risen in many countries over the past decade. The greatest risk factor associated 
with the development of HCC is hepatitis B and C virus infection. Hepatitis infection is 
believed to increase the risk of developing HCC by 20 fold and is the major etiological factor 
in more than 80% of HCC cases (Anzola, 2004). Other main risk factors include excessive 
alcohol consumption, non alcoholic steatohepatitis, exposure to environmental toxins such 
as aflatoxin B, hemochromatosis, cirrhosis, diabetes and obesity (El-Serag et al., 2006; 
Hassan et al., 2010; Whittaker et al., 2010). 
The standard treatments for early stage HCC, such as surgical resection and liver 
transplantation, can cure certain population of patients. However, due to the asymptomatic 
nature of early HCC and lack of effective screening strategies, 80% of patients present with 
advanced HCC at the time of diagnosis (Thomas and Abbruzzese, 2005). These patients 
have rather limited treatment options which are mainly palliative. If the patient has 
developed HCC that is surgical unresectable, systemic treatments are commonly used. 
However, conventional chemotherapy with cytotoxic agents is not very effective in 
changing the progress of the tumor growth. Consequently, the mortality rate for advanced 
stage HCC is quite high, and 5 year survival rate for patients with HCC is only 7% (Bosch et 
al., 2004; Whittaker et al., 2010). There is clearly an urgent medical need to develop new 
effective and well-tolerated HCC treatment options.  
In recent decades, tremendous progress has been made toward better understanding the 
molecular mechanisms of oncogenic processes. Many cell signaling pathways involved in 
tumor pathogenesis have been identified, leading to the identification of new molecular 
targets for therapeutic development. Unlike conventional chemotherapy which utilizes 
broad spectrum cytotoxic agents, targeted therapy acts directly and specifically on the 
components that regulate tumorigenesis. This strategy has shown clinical benefits in various 
tumor types, such as breast, colorectal and lung cancers (Ansari et al., 2009; Slamon et al., 
2001; Takahashi and Nishioka, 2011). Several major cellular signaling pathways have been 
implicated in HCC, and below we will review those pathways and discuss the potential to 
target the molecular components within those signaling pathways. 
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2. Major signaling pathways 
 
Fig. 1. Major cellular signaling pathways involved in hepatocellular carcinoma 
tumorigenesis  
2.1 Wnt/-catenin pathway  
Wnt signaling pathway involves three main components which include the cell surface, the 
cytoplasm, and the nucleus (Giles et al., 2003). At the cell membrane, Wnt ligands form 
complexes with Frizzled receptors and LRP5 or LRP6 co-receptors (Dale, 1998; Wehrli et al., 
2000). There are at least 19 known human Wnt family genes and 10 Frizzled family genes, 
and most Wnt proteins can bind to multiple Frizzled receptors and vice versa (Wang et al., 
1996). This ligand receptor interaction can be additionally regulated by other secreted 
factors and cell surface proteins. For example, soluble forms of Frizzled proteins compete 
with cell membrane Frizzled receptor for Wnt ligands (Finch et al., 1997). And DKK proteins 
block Wnt signaling by binding to LRP6 co-receptor (Fedi et al., 1999).  
In the cytoplasm, -catenin associates with a multiprotein complex which includes tumor 
suppressor proteins APC, axin, and Ser/Thr kinase GSK3. Axin and APC form a structural 
scaffold that allows GSK3 to phosphorylate -catenin. Phosphorylation of -catenin targets 
it for ubiquitination and protein degradation (Clevers, 2006; Gordon and Nusse, 2006). 
Therefore, under basal conditions, in the absence of Wnt ligands, -catenin is continuously 
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degraded in the cytosol. Upon Wnt binding, axin is recruited to the membrane to LPR5 and 
the -catenin destruction complex is then inactivated. This allows the unphosphorylated -
catenin to accumulate and to translocate into the nucleus (Clevers, 2006; Gordon and Nusse, 
2006). The nuclear -catenin then forms a complex with TCF/LEF family of DNA binding 
transcription factors to activate TCF/LEF target genes. Many of the target genes are 
involved in cell proliferation, such as cyclin D1 (Shtutman et al., 1999). 
Besides regulating gene transcription, -catenin also participates in cell–cell adhesion. Cell-
cell adhesion and separation are important physiological processes involved in 
development as well as tumor metastasis. It is known that cadherin mediated adhesion is 
regulated by -catenin. The formation of stable cell–cell adhesions depends on the integrity 
of a core complex including E-cadherin, -catenin and -catenin. -catenin binds directly to 
the cytoplasmic domain of E-cadherin and such association is regulated by the 
phosphorylation state of -catenin (Nelson and Nusse, 2004). 
Wnt signaling clearly plays important roles in normal liver function as 8 out of the total 19 
Wnt ligands are expressed in hepatocytes (Thompson and Monga, 2007). Both LRP5 and 
LRP6 and 9 of 10 Frizzled receptors are expressed in normal liver (Fujino et al., 2003; Zeng et 
al., 2007). Evidence has suggested that the Wnt signaling pathway is critically involved in 
liver development and postnatal liver homeostasis. In addition, this pathway is also 
associated with many other important liver functions, such as ammonia and nitrogen 
metabolism, bile acid homeostasis, drug detoxification and injury recovery (Behari, 2010; 
Takigawa and Brown, 2008).  
Multiple lines of evidence link aberrant Wnt signaling to HCC. Wnt signaling pathway 
activation is frequently reported in liver carcinoma. It has been demonstrated that there are 
significant changes in subcellular localization of -catenin and -catenin-associated cell 
adhesion molecules in HCC (Ihara et al., 1996). Studies have shown that 50-70% of liver 
tumors have increased levels of -catenin in the cytoplasm and in the nucleus (Wong et al., 
2001). Such accumulation can potentially provide tumor cells a growth advantage by 
promoting proliferation and inhibiting differentiation. A transgenic mouse model 
overexpressing -catenin developed severe hepatomegaly (Giles et al., 2003). There are also 
studies associating -catenin mutations or activation with worsened HCC outcome such as 
larger tumor size and increased vascular invasion (Behari, 2010).  
Accumulation and stabilization of -catenin could be a direct result from point mutations or 
deletions in the -catenin gene, which is found in 12-26% of HCC (Giles et al., 2003). Such 
dominant gain-of-function mutations usually occur at the N-terminal phosphorylation sites 
on -catenin, including the sites phosphorylated by GSK3 that regulate -catenin 
degradation (Takigawa and Brown, 2008). Mutations at these positions disrupt recognition 
by GSK3resulting in more stable -catenin protein. Besides gain of function mutations in 
positive modulators of Wnt signaling such as -catenin, the Wnt pathway can also be 
activated from loss-of function mutations in negative modulators such as Axin and APC 
(Takigawa and Brown, 2008). However, frequencies of -catenin accumulation in HCC 
determined by immunostaining are much higher than the known incidence of Wnt pathway 
mutations. Thus, other causes of -catenin accumulation may also exist. Epigenetic changes 
could be a contributing factor, which leads to higher gene expression without any mutations 
in the gene (Takigawa and Brown, 2008). 
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Although there is little doubt about the strong correlation between aberrant Wnt signaling 
and HCC, the precise role of activated Wnt pathway in the pathogenesis of liver tumor is 
less well understood. It has been shown that pharmacologic inhibition of -catenin 
decreases survival of hepatoma cells (Behari et al., 2007). Inactivation of -catenin 
suppressor APC led to spontaneous development of HCC in a mice model, suggesting the 
direct contribution from activated Wnt signaling to hepatocarcinogenesis (Colnot et al., 
2004). However mice overexpressing a gain-of-function -catenin mutant (exon 3 deletion) 
only showed increased susceptibility to developing HCC after exposure to carcinogen 
diethylnitrosamine (DEN), instead of developing spontaneous liver tumor (Harada et al., 
2002). These results suggest that the role of the Wnt pathway in the development of liver 
cancer is highly context-dependent and involves cross-talk with other pathways. 
Nonetheless, components of the Wnt pathway may represent potential therapeutic 
intervention points for treating HCC. 
Several approaches could be envisioned to target Wnt pathways. Extracellularly, it is 
possible to design molecules to disrupt Wnt ligand-receptor complexes, preventing 
initiation of the signaling events. For this approach, Wnt ligands, extracellular Wnt 
regulators such as DKKs, SFRPs proteins, and members of the receptor complexes can all be 
targeted. These proteins themselves or variants could be directly considered as candidates 
for drug developments. Alternatively, antibodies or other modalities that could block ligand 
receptor interactions may also be explored for therapeutic development. Intracellular 
components could also be targeted. Small molecule ligands toward kinases of the signaling 
pathway could also be screened that may regulate Wnt signaling. In addition, small 
molecule antagonists have been identified to interfere with the binding between -catenin 
and TCF/LEF proteins or its coactivator CEBP, blocking downstream gene activation 
(Dahmani et al., 2011). However, due to the inherent complexity of Wnt signaling in the 
liver, further research is needed to fully understand the implications of therapeutic 
inhibition of the pathway in HCC. 
2.2 VEGF pathway 
Angiogenesis is critical for cancer development. Tumor cells require oxygen and nutrients 
for survival and proliferation and  they need to be located within 100 to 200 m from blood 
vessels to obtain an adequate supply of oxygen (Carmeliet and Jain, 2000). Solid tumors 
smaller than 1 to 2 cubic millimeters are not vascularized (Hawkins, 1995). However, 
beyond the critical volume of 2 cubic millimeters, new blood vessels need to be recruited to 
supply oxygen and nutrients and to remove metabolic wastes (Hawkins, 1995). 
Neovascularization also facilitates the dissemination of cancer cells throughout the entire 
body eventually leading to metastasis formation. 
HCC is a hypervascular tumor and many pro-angiogenic factors are over-expressed in HCC 
cells and in the surrounding microenvironment (Shen et al., 2010). Among them, VEGF 
receptor signaling is one of the most well studied. The major VEGF that mediates tumor 
angiogenesis is VEGF-A, and it has several splicing variants that can be produced 
simultaneously. The most predominant forms are VEGF-A121 and VEGF-A165. Other 
members in the VEGF family include Placenta growth factor (PlGF), VEGF-B, VEGF-C, and 
VEGF-D (Kaseb et al., 2009; Roskoski, 2007). VEGF signals through VEGF receptor (tyrosine 
kinase receptor) on the cell surface. There are three main subtypes of VEGF receptors, 
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numbered 1, 2 and 3 (Kaseb et al., 2009; Roskoski, 2007). They all have an extracellular 
region consisting of 7 immunoglobulin-like domains, a single transmembrane domain, and 
an intracellular portion containing a split tyrosine-kinase domain. VEGF ligand binding 
induces dimerization and autophosphorylation of VEGF receptors. Phosphorylated tyrosine 
residues in the receptor serve as a docking site for various signal transduction proteins that 
can eventually activate cellular processes involved in angiogenesis. For example, VEGFR-2 
phosphorylation activates PLC- which in turn leads to protein kinase C activation (PKC). 
PKC can activate MAP kinase signaling and promote cell proliferation as well as increase 
vascular permeability through activation of endothelial nitric oxide synthase (Kaseb et al., 
2009; Roskoski, 2007). VEGF also induce activation of Rho GTPase, which plays a crucial 
role during angiogenesis processes such as vascular permeability, extra cellular matrix 
degradation, cellular migration and invasion (van der Meel et al., 2011). 
Among the three VEGF receptors, VEGFR-2 appears to mediate almost all of the known 
cellular responses to VEGFs. The activation of VEGFR-2 in endothelial cells results in their 
proliferation, migration, and increased survival and promotes vascular permeability (Kaseb 
et al., 2009; Roskoski, 2007). The function of VEGFR-1 is less known. Although it has higher 
affinity for VEGF than VEFGR-2, it has weak tyrosine kinase phosphorylation activity 
following ligand stimulation. Activation of VEGFR-1 has no direct proliferative or 
cytoskeletal effects. It is possibly involved in modulating VEGFR-2 activity. VEGF-C and 
VEGF-D, but not VEGF-A, are ligands for a third receptor (VEGFR-3), which is important 
for lymphangiogenesis (Kaseb et al., 2009; Roskoski, 2007). 
The VEGF pathway is clearly important for HCC pathogenesis. Expression of VEGF mRNA 
in liver tumors was found in a majority of HCC patients. And the expression of VEGF 
steadily increases with the progression of the hepatocarcinogenic process from a normal 
liver, to a dysplastic nodule, to HCC (Yamaguchi et al., 1998). The levels of VEGF mRNA 
expression in tumors with tumorous emboli and in poor-encapsulated tumors were higher 
than those without tumorous emboli and in well-encapsulated tumors. The principle route 
of HCC dissemination and metastasis is through the portal vein in the liver and VEGF 
mRNA level correlated well with portal vein tumor thrombus (PVTT) formation of HCC, 
suggesting VEGF may play an important role in HCC invasion and metastasis (Zhou et al., 
2000). Immunohistochemical staining also detected very high VEGF expression in well-
differentiated HCC as well as areas surrounding the HCC tissues, where inflammatory cell 
filtration was apparent. High serum VEGF levels have been shown to correlate with poor 
response to chemotherapy and poor survival among HCC patients. Increased preoperative 
serum VEGF may also predict high incidence of tumor recurrence after surgical resection 
(Whittaker et al., 2010). Furthermore, increased VEGF expression has also been detected in 
cirrhotic and dysplastic livers, which often lead to liver cancer (El-Assal et al., 1998). 
The most direct evidence supporting the role of the VEGF signaling pathway in HCC came 
from recent progress in molecular targeted therapy inhibiting this pathway. Bevacizumab, 
an anti–VEGF monoclonal antibody was tested in patients with unresectable HCC and 
resulted in significant disease-stabilizing effect (Siegel et al., 2008). Clinical effects were 
assessed by tumor regression and progression-free survival (PFS). Of the 46 patients in the 
study, 13% had objective response and 65% were progression free at 6 months. The mean 
PFS time was 6.9 months and median overall survival time is 12.4 months. Overall survival 
rates were 53% at 1 year, 28% at 2 years and 23% at 3 years. Treatment was associated with 
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significant reductions in tumor arterial enhancement and circulating VEGF-A level. Besides 
VEGF antibody, small molecule VEGF inhibitors have also been developed and tested in 
clinic. Sorafenib, an inhibitor targeting the VEGF pathway has been shown to prolong 
overall survival in patient with advanced HCC (Llovet et al., 2008). In a randomized, 
placebo-controlled phase III trial, sorafenib prolonged median survival time of advanced 
HCC patients by 2.8 months, from 7.9 months in the placebo group to 10.7 months in the 
sorafenib treatment group. Time to radiologic progression was delayed by 2.7 months, from 
2.8 months to 5.5 months. This result is quite significant since no effective systemic therapy 
ever existed for patients with advanced hepatocellular carcinoma before the sorafenib trial. 
There are several other VEGF small molecule inhibitors that are currently being tested in the 
clinic for HCC treatment including, sunitinib, vatalanib, cediranib, brivanib, and linifanib 
(Shen et al., 2010; Whittaker et al., 2010). Studies have also been carried out to assess the 
benefit of the combined therapy using those compounds. 
2.3 FGF pathway 
Supported by various mouse genetic models as well as human genetic studies, aberrant 
FGF/FGFR signaling is clearly associated with tumorigenesis (Beenken and Mohammadi, 
2009; Knights and Cook, 2010; Krejci et al., 2009; Turner and Grose, 2010). Signaling is 
activated upon FGF ligands binding to the FGF receptors on the cell surface. There are more 
than 20 different FGFs in the FGF family, making it the largest family of growth factors. 
Fibroblast growth factor receptors consist of an extracellular ligand binding domain, a single 
transmembrane domain, and an intracellular domain with tyrosine kinase activity. The 
extracellular domain of the FGF receptor is composed of three immunoglobin-like domains. 
Alternative splicing of four FGF receptors genes (FGFR1-4) results in over 48 different 
isoforms of FGFRs, and they have different affinity towards different FGF ligands and have 
distinct expression patterns (Ornitz and Itoh, 2001; Ornitz et al., 1996). FGFRs are tyrosine 
kinase receptors that upon ligand binding induce dimerization and kinase activation in the 
presence of the co-factor, heparan sulfate (Plotnikov et al., 1999). Phosphorylation of the 
tyrosine residues on the receptor provides docking sites for downstream adaptor proteins, 
which can couple to the activation of different intracellular signaling pathways. One of the 
key adaptor proteins of FGF receptors is FGF substrate 2 (FRS2) which can be 
phosphorylated by FGFR receptors and recruit more adaptor proteins such as son of 
sevenless (SOS) and growth factor receptor-bound 2 (GRB2) to activate RAS GTPase 
(Eswarakumar et al., 2005). RAS GTPase promotes several downstream signaling, such as 
Wnt, MAPK, and PI3K/Akt pathways (Knights and Cook, 2010). These FGF downstream 
signaling pathways have all been implicated in several aspects of tumorigenesis, such as 
proliferation, survival, cell migration and invasion, as well as angiogenesis (Balmanno and 
Cook, 2009; Dailey et al., 2005; Presta et al., 2005; Xian et al., 2005). In HCC, it has been 
shown that plasma FGF2 level was significantly increased (Hsu et al., 1997) and 
overexpression of FGFR1 in hepatocytes accelerated the growth of HCC chemically induced 
by DEN in a mouse model (Huang et al., 2006). 
Recently, attention has focused on a unique FGF family member, FGF19, and its 
involvement in the development of HCC (Nicholes et al., 2002; Wu and Li, 2009). FGF19 
belongs to a unique FGF subfamily that has weakened affinity towards heparan sulfate. The 
reduced affinity liberates FGF19 from tissues where it is expressed, allowing it to act as an 
endocrine hormone. Furthermore, FGF19 requires Klotho as a co-receptor in activating FGF 
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receptors. In the presence of Klotho, FGF19 is able to activate similar downstream signaling 
through FGF receptors (Kurosu et al., 2007; Wu et al., 2007). 
First evidence connecting FGF19 with HCC came from a transgenic FGF19 mice model, 
where human FGF19 driven by myosin promoters was overexpressed from skeleton muscle, 
resulting in elevated serum FGF19 protein levels (Nicholes et al., 2002). HCC development 
was observed in these FGF19 transgenic mice at 8-10 months, while no tumors were 
observed in wild type control mice. Tumors occurred in different liver lobes and were either 
solitary or multifocal. Histological staining showed neoplastic cells invasion and 
replacement of normal hepatocytes (Nicholes et al., 2002). Hepatocytes are normally 
mitotically quiescent in the liver. However, in case of HCC, hepatocellular proliferation is a 
prerequisite for transformation. In vivo 5-bromo-2'-deoxyuridine (BrdU) labeling was 
performed to assess the proliferation in FGF19 transgenic mice. BrdU-labeling index of 
hepatocytes was eight fold higher in the transgenic mice than age-matched wild type mice 
at 2 to 4 months of age (Nicholes et al., 2002). Furthermore, recombinant FGF19 protein also 
induced a significant higher BrdU-labeling index after being injected into normal mice 
(Nicholes et al., 2002; Wu et al., 2010a; Wu et al., 2010b). These results strongly support the 
notion that FGF19 can induce hepatocellular proliferation which eventually leads to 
development of HCC. 
FGF19 is able to activate the Wnt pathway in hepatocytes, and 44% of neoplastic 
hepatocytes in FGF19 transgenic mice have nuclear staining for -catenin (Nicholes et al., 
2002; Pai et al., 2008). Since aberrant Wnt signaling correlates strongly with HCC 
tumorigenesis, this may be one mechanism whereby FGF19 induces liver tumor formation. 
To test the hypothesis of whether FGF19 could be a valid target in HCC treatment, a 
monoclonal anti-FGF19 antibody was generated and tested in tumor inhibition. Anti-FGF19 
antibody or control antibody were used to treat DEN accelerated HCC formation in FGF19 
transgenic mice (Desnoyers et al., 2008). After six months of antibody treatment, all the 
animals treated with control antibody developed multifocal, large HCCs throughout the 
liver lobes while almost none of the mice treated with FGF19 antibody had liver tumors. The 
same anti-FGF19 antibody was also tested in xenograft mice models (Desnoyers et al., 2008). 
Mice xenografted with colon cancer cell lines HCT116 and Colo201 were injected with anti-
FGF19 antibody twice weekly. At day 35, FGF19 antibody suppressed tumor growth by 57% 
compared to the control in HCT116 group and 64% growth inhibition was achieved in 
Colo201 animals treated with the antibody. These data suggest that targeting FGF19 could 
be a valid strategy for HCC treatment. 
The main candidate FGF receptor mediating FGF19 induced tumorigensis in liver is 
believed to be FGFR4, which is the predominant FGF receptor expressed in the liver. Strong 
FGFR4 mRNA was detected in hepatocytes adjacent to central vein by in situ hybridization, 
and the hepatic dysplasia foci and BrdU labeling from FGF19 transgenic livers are also 
located around central vein. In addition, activation of FGFR4 alone was sufficient to induce 
hepatocyte proliferation (Wu et al., 2010a; Wu et al., 2010b) and FGF19 induced hepatocytes 
proliferation was not observed in FGFR4 knockout mice, confirming the role played by 
FGFR4 in hepatocarcinogenesis (Wu et al., 2011). 
FGFR4 has been implicated in HCC in many literature reports (Yang et al., 2011). FGFR4 is 
frequently overexpressed in patients with hepatocellular carcinoma (Yang et al., 2011). 
siRNA against FGFR4 in liver cancer lines HuH7 is able to suppress -fetoprotein 
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production (Yang et al., 2011). However, there have also been reports showing genetic 
deletion of FGFR4 in mice results in faster progression of DEN-accelerated hepatocellular 
carcinoma, suggesting that FGFR4 suppresses hepatoma proliferation (Huang et al., 2009). 
The contribution of FGFR4 in HCC progression requires further clarification. 
2.4 MAPK pathway 
Mitogen-activated protein kinase (MAPK) is serine-threonine kinase that is involved in a 
variety of cellular activities. There are three members in the mammalian MAPK family, 
extracellular signal-regulated kinase (ERK), c-Jun NH2-terminal kinase (JNK), and p38 (Kim 
and Choi, 2010; Min et al., 2011). Among them, ERK signaling pathway is the most studied 
for its involvement in promoting cell proliferation, migration, survival, and its association 
with tumorigenesis and tumor progression (Gollob et al., 2006). Recent data also implicate 
JNK and p38 as playing important roles during HCC development (Min et al., 2011).  
The ERK pathway is ubiquitous and can be activated by various receptors, particularly 
receptor tyrosine kinases (RTKs). Upon ligand binding, the RTKs dimerize which leads to 
activation of the intracellular tyrosine kinase domain. Activated kinase results in receptor 
phosphorylation on tyrosine residues, that then serves as docking sites for adaptor proteins 
such as GRB2 and SOS (Schulze et al., 2005; Zarich et al., 2006). Upon docking to the 
receptors, the GRB2 and SOS activate the small GTPase RAS (HRAS, NRAS and KRAS) 
which in turn will activate the serine/threonine kinase RAF. RAF is a MAPK kinase kinase 
(MAP3K), and it has three isoforms, ARAF, BRAF and CRAF. Activated RAF will 
phosphorylate and activate MEK, a MAPK kinase (MAP2K) and MEK is the kinase for ERK 
(ERK1 and ERK2) (Avruch et al., 2001; Malumbres and Barbacid, 2003). 
There are more than 100 substrates downstream of ERK, and many of them are transcription 
factors. The altered levels and activities of the transcription factors by ERK activation can 
lead to altered expression levels of genes that are important for cell cycle progression (Davis, 
1995). For example, ERK can phosphorylate and activate C-myc, a transcription factor that 
regulates the expression of many target genes involved in cell growth and proliferation. C-
Myc is a strong proto-oncogene and can be found unregulated in many types of cancers 
(Penn et al., 1990). ERK also directly phosphorylates kinase substrates such as myosin light 
chain kinase, calpain, and focal adhesion kinase, which promotes cell migration (Huang et 
al., 2004). Furthermore, the ERK pathway can regulate proteins involved in apoptotic 
pathway such as BIM and MCL1, promoting survival of cancer cells (Balmanno and Cook, 
2009). 
Given the contribution of ERK signaling towards cell proliferation, migration and survival, 
it is not surprising to see constitutive activation of the ERK pathway in many tumors. In fact, 
genes along the ERK pathway, such as HRAS, KRAS, and CRAF, are often upregulated in 
HCC. One study has shown that CRAF is overexpresed among all 30 HCC tissue samples 
tested (Hwang et al., 2004). Immunostaining also showed around 7 fold increase of MEK 
phosphorylation in HCC tissues compared to surrounding benign liver tissues (Huynh et 
al., 2003). Other studies also found that phosphorylated ERK level is higher in HCC tissues 
and ERK activation is associated with aggressive tumor behavior (Schmitz et al., 2008). In 
addition, negative regulator proteins of MAPK/ERK pathway such as Sprouty and DUSP1 
are down-regulated in HCC tumors (Calvisi et al., 2008) (Yoshida et al., 2006). Sustained 
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activation of ERK signaling can also occur due to point mutations in the RAS gene, which 
leads to constitutive CRAF activation (Downward, 2003; Whittaker et al., 2010). Mutation in 
the RAS gene has been reported in 10-30% of HCC tumors (Whittaker et al., 2010). The 
involvement of the ERK pathway in HCC is further confirmed by preclinical studies using 
the MEK inhibitor, AZD6244, which blocks proliferation and promotes apoptosis in primary 
HCC cells (Huynh et al., 2007a; Huynh et al., 2007b). AZD6244 also suppresses tumor 
growth in HCC xenograft model in a dose-dependent manner. And tumor growth inhibition 
after AZD6244 treatment correlates with inactivation of ERK, up-regulation of apoptotic 
genes such as caspase-3 and 7 and down-regulation of cell cycle regulators such as cyclin 
D1. It has also been shown that AZD6244 can induce a synergistic effect in tumor 
suppression when combined with chemotherapeutic agent doxorubicin (Huynh et al., 2007a; 
Huynh et al., 2007b). 
JNK is another major MAPK signaling pathway. It can be activated by two MAPK kinases, 
MKK4 and MKK7, and its downstream substrates include c-Jun (Keshet and Seger, 2010). 
JNK signaling can be activated by various cytokines and environmental factors. It has been 
demonstrated that JNK1 and JNK2 regulate stress-induced apoptosis, and increased JNK 
activity has also been shown to enhance proliferation of mouse embryonic fibroblasts 
(MEFs) (Das et al., 2011). There is strong correlation between activated JNK signaling and 
HCC. For example, one study has shown that JNK1 is over-activated in 17 out of 31 samples 
(55%) from Chinese HCC patients (Chang et al., 2009). The activation in JNK1 is associated 
with increased tumor size and a lack of encapsulation of the tumors. In addition, JNK1 
activation also associates with increased histone H3 lysines 4 and 9 tri-methylation, which 
leads to up-regulation of genes promoting cell growth (Chang et al., 2009). 
Direct evidence demonstrating the role of JNK pathway in HCC development comes from 
studies in mouse models. JNK1 knockout mice had a significant reduction in liver 
tumorigenesis chemically induced by DEN and hepatocyte proliferation also decreased in 
those animals (Hui et al., 2008). It was proposed that mice lacking JNK1 have increased 
expression of p21, a cell cycle inhibitor. Blocking JNK activity using pharmacological 
inhibitor D-JNKI1 reduced growth of both xenografted human HCC cells and DEN-induced 
mouse liver cancers, further supporting the role played by JNK pathway in HCC 
development (Hui et al., 2008). 
The activation of p38 is induced by MKK3, 4, and 6, as well as autophosphorylation. Its 
substrates include transcription factors such as p53 and protein kinases such as MK2 and 
MK5 (Min et al., 2011). Interestingly, unlike ERK and JNK pathways, p38 seems to play a 
suppressive role in HCC (Min et al., 2011). It was shown that human embryonic fibroblasts 
displayed enhanced proliferation upon treatment with a p38 inhibitor (SB203580) (Wang et 
al., 2002). p38 negatively regulates proliferation partly through suppression of the JNK 
pathway, which is known to promote cell proliferation. Depending upon the cellular 
context, p38 can enhance the protein level of JNK phosphatase and repress the activities of 
JNK kinases (Wagner and Nebreda, 2009). In p38 deficient fetal liver cells and liver tumor 
cells, the JNK pathway activity was found to be increased. Direct evidence supporting the 
suppressive role of p38 in HCC came from a study using mice with liver-specific deletion of 
p38, where enhanced hepatocyte proliferation and tumor development were observed 
during liver carcinogenesis (Hui et al., 2007). After DEN treatment, p38 deficient mice 
clearly developed more tumors in the liver and had larger average tumor size compared 
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with control mice. Moreover, inactivation of JNK pathway with -JNKI1 suppressed the 
hyperproliferation in p38-deficient animals (Hui et al., 2007). 
In summary, numerous data have clearly demonstrated the deep involvement of MAPK 
signaling pathways during liver carcinogenesis. Identifying pharmacological intervention 
points along these pathways could be considered as a very promising strategy for 
combating HCC. 
2.5 PI3k/AKT/mTOR pathway 
Phosphoinositide 3 kinase (PI3K) is an intracellular signal transducer enzyme that can 
phosphorylate the hydroxyl group of phosphatidylinositol (Vanhaesebroeck and Waterfield, 
1999). It belongs to a large family of PI3K-related kinases (Kuruvilla and Schreiber, 1999). PI3K 
is comprised of a catalytic subunit and a regulatory subunit. The regulatory subunit p85 can 
interact with phosphotyrosines on activated RTKs that recruit the enzyme to the plasma 
membrane and activate the enzymatic activities (Paez and Sellers, 2003). PI3K produces the 
lipid second messenger phosphatidylinosoltriphosphate, which is absent in resting cells but 
can be acutely produced in response to activated PI3K (Vanhaesebroeck and Waterfield, 1999).  
Akt is a serine-threonine kinase downstream of PI3K. It contains a pleckstrin homology (PH) 
domain in the N-terminus, a central catalytic kinase domain and a C-terminus regulatory 
domain (Paez and Sellers, 2003). The PH domain will bind to phosphatidylinosoltriphosphate 
with high affinity. Upon PI3K activation and phosphatidylinosoltriphosphate production, Akt 
is recruited to the plasma membrane through its PH domain together with another PH domain 
containing protein, phosphoinositide dependent kinase 1 (PDK1). PDK1 then phosphorylate 
key residues in the kinase domain activation loop of Akt to activate Akt kinase activity (Paez 
and Sellers, 2003). 
Activated Akt phosphorylates multiple protein substrates and regulates a variety of critical 
cellular activities (Paez and Sellers, 2003; Whittaker et al., 2010). Mammalian target of 
rapamycin (mTOR) is one of the most important downstream effectors of Akt. Akt 
phosphorylates the tuberous sclerosis complex (TSC1/TSC2) which activates the small G 
protein, Ras homolog enriched in brain (Rheb). Rheb, in its GTP-bound state, can activate 
mTOR. mTOR is a serine-threonine protein kinase that also belongs to PI3K-related kinase 
family. It is a large protein consists of tandem HEAT repeats, FAT (FRAP-ATM-TRRAP) and 
FATC (FAT C-terminus) domains, FKBP12-rapamycin binding domain (FRB), and  C-
terminus catalytic kinase domain that resembles the catalytic domain of PI3K (Wullschleger 
et al., 2006). For mTOR to activate its signaling cascade, it must form the ternary complex 
mTORC1 (mTOR Complex-1) or mTORC2 (mTOR Complex-2), but mTOR is the catalytic 
subunit of both of these two complexes. mTORC1 complex contains mTOR, RAPTOR 
(Regulatory Associated Protein of mTOR), mammalian LST8/G-protein ┚-subunit  
like protein (mLST8/G┚L), PRAS40 and DEPTOR. mTORC2 complex consists of  
mTOR, rapamycin-insensitive companion of mTOR (Rictor), G┚L, and mammalian stress-
activated protein kinase interacting protein 1 (mSIN1) (Wullschleger et al., 2006; Paez and 
Sellers, 2003).  
Another very important component of PI3K/Akt/mTOR pathway is PTEN (phosphatase and 
tensin homolog). It consists of a phosphatase domain which carries out the enzymatic function 
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and a C2 domain which binds the phospholipid membrane. PTEN dephosphorylates 
phosphatidylinosoltriphosphate and serves as a negative regulator of PI3K/AKT/mTOR 
pathway (Paez and Sellers, 2003). 
mTOR controls several important cellular processes including regulation of protein 
translation. Abberent protein translation often leads to abnormal cell growth and 
tumorigenesis (Petroulakis et al., 2006; Wullschleger et al., 2006). mTOR enhances 
translation initiation via two major targets, the eIF4E binding proteins (4E-BPs) and the 
ribosomal protein S6 kinases (S6K1 and S6K2). Eukaryotic mRNAs contain a ‘cap’ structure, 
m7GpppN at the 5’ end and can be specifically recognized by the initiation factor eIF4E, 
which associates with eIF4G and eIF4A to form eIF4F complex and initiate cap-dependent 
translation. 4E-BP binds to eIF4E and inhibits eIF4F complex formation. Upon 
phosphorylation of 4E-BP by mTOR, eIF4E is released to stimulate translation initiation. S6 
kinase is activated by mTOR and phosphorylates 40S ribosomal protein S6, which leads to 
increased translation of a subset of mRNAs containing 5’ tract of oligopyrimidine (TOP). 5’ 
TOP mRNAs encode ribosomal proteins, elongation factors, the poly-A binding protein and 
other components of the translational machinery. Therefore, stimulation of the 5’ TOP 
mRNA translation by S6 results in up-regulation of the overall cellular translation capacity 
(Petroulakis et al., 2006). 
The PI3K/Akt/mTOR signaling pathway is known to be up-regulated in various carcinoma 
cell lines, as well as in human ovarian and breast carcinomas (Altomare et al., 2004) 
(McAuliffe et al., 2010). For HCC, one study has shown overexpression of phospho-mTOR 
in 15% of liver tumors. Phospho-mTOR also positivity correlated with increased expression 
of total S6 kinase, which was found in 45% of the cases (Sahin et al., 2004). Elevated Akt 
phosphorylation was also found in 23% of HCC and implicated early HCC recurrence and 
poor prognosis (Boyault et al., 2007). There is also a high frequency (35.6%) of somatic PI3K 
mutations in HCC specimens (Lee et al., 2005). PTEN, the negative component of the 
PI3K/Akt/mTOR, is mutated in 5% of HCC and its expression is reduced in half of all HCC 
tumors, leading to the over activation of the pathway (Whittaker et al., 2010). In HCC 
patients, reduced PTEN expression has been associated with advanced tumor stage, high 
recurrences rate and poor survival outcome, suggesting inactivation of PTEN is involved in 
the pathogenesis of HCC (Hu et al., 2003). A study using hepatocyte-specific PTEN deficient 
mice further supported such a connection, by demonstrating that at 80 weeks of age, 66% of 
PTEN-deficient mice developed HCC (Horie et al., 2004). 
Given the strong association between aberrant PI3K/Akt/mTOR signaling and HCC, 
pharmacological inhibition of this pathway could be a viable HCC treatment strategy. The 
mTOR inhibitor everolimus has been shown to decrease the growth of HCC cell line 
(Villanueva et al., 2008). Everolimus also induced a significant delay of tumor growth in a 
HCC xenograft mice model (Villanueva et al., 2008). In a separate study, the mTOR inhibitor 
sirolimus was tested in a rat HCC model and the treatment resulted in significantly longer 
survival time, smaller tumor size, and fewer extrahepatic metastases in those animals 
(Semela et al., 2007). Sirolimus has also been tested in human HCC patients, and it induced a 
partial response in 5% of the patients and tumor stabilization for at least 3 months in 24% of 
the patients. Another study has shown that 33% of patients partially response to sirolimus 
treatment (Rizell et al., 2008; Semela et al., 2007). Several new clinical trials are currently 
testing mTOR inhibitors and its combination with other therapies among HCC patients. 
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2.6 Other miscellaneous pathways 
The EGFR (epidermal growth factor receptor) is a receptor tyrosine kinase which is 
activated by ligands including epidermal growth factor (EGF) and transforming growth 
factor ┙ (TGF-┙) (Herbst, 2004). Upon activation, EGFR forms a dimer and 
autophosphorylates the tyrosine residues in its intracellular cytoplasmic domain, which in 
turn leads to initiation of many downstream signal transduction cascades (Herbst, 2004). 
The EGFR signaling pathway is one of the most important pathways that regulate growth, 
survival, proliferation, and differentiation in mammalian cells. Numerous studies have 
shown that aberrant EGFR signaling plays a vital role in tumor angiogenesis and 
proliferation and agents that specifically block this pathway showed efficacy in several 
types of solid tumors (Zhang et al., 2007). For HCC, EGFR overexpression was detected 
among 40–70% of the tumors and TGF-┙ level was also elevated in pre-neoplastic HCC 
(Feitelson et al., 2004). Thus, targeting EGFR may also show beneficial effect for HCC 
patients. EGFR blocking agents include both small molecule tyrosine kinase inhibitors and 
monoclonal antibodies targeting the receptor. Erlotinib is a low molecular weight inhibitor 
of EGFR kinase (Thomas et al., 2007). It is able to suppress the growth of HCC cell lines  
in vitro. Furthermore, during a Phase 2 clinical trial, 17 out of 40 patients with unresectable 
HCC achieved stable disease at 16 weeks of erlotinib treatment. Progression-free survival at 
16 weeks was 43% and median overall survival was 43 weeks, longer than the historical 
controls. Monoclonal antibody cetuximab which targets the extracelluar domain of EGFR 
has also been tested in HCC (Zhu et al., 2007). Although cetuximab was able to inhibit cell 
growth and induce apoptosis in some HCC cell lines, the results from clinical trials testing 
its efficacy among HCC patients have been inconsistent. Currently, several more anti-EGFR 
pathway compounds are being tested in clinic, in some cases in combination with other 
therapeutic methods. The results from those trials might further clarify the benefit of the 
EGFR blocking agents for HCC. 
Deregulation of the insulin-like growth factor (IGF) pathway has also been implicated in the 
development of HCC (Scharf et al., 2001). IGF-1 and 2 bind to IGF receptor IGF-1R and 
activate downstream signaling (Alexia et al., 2004). IGF signaling pathway regulates cell 
proliferation, motility and apoptosis. Pronounced alterations in the expression of 
components of the IGF pathway have been reported during hepatocarcinogenesis 
(Whittaker et al., 2010). IGF-2 is overexpressed in 16-40% of HCC and around 30% of HCCs 
overexpress IFG-1R (Cariani et al., 1988). Neutralizing IGF-2 has been shown to reduce cell 
proliferation and increase apoptosis in HCC cell lines (Lund et al., 2004). Furthermore, a 
monoclonal antibody that selectively inhibits IGF-1R was not only able to decrease viability 
and proliferation of liver cancer cells in vitro but also delay tumor growth and prolong 
survival in HCC xenograft mice model (Tovar et al., 2010). Several small molecules and 
monoclonal antibodies targeting IGF-1R are now under early clinical development. 
In HCC, the transforming growth factor-beta (TGF-┚) pathway regulates several steps in 
tumor progression, including angiogenesis, production of the extracellular matrix and 
immune suppression (Giannelli et al., 2011). It is also involved in initiating signaling cascade 
which promotes liver fibrosis, cirrhosis and subsequent progression to HCC (Giannelli et al., 
2011). Increased levels of TGF-┚ in HCC patients' sera and urine are associated with disease 
progression (Yasmin Anum et al., 2009; Tsai et al., 1997). Specific small molecule inhibitors 
targeting TGF-┚ type I receptor (TGF-┚RI) kinase LY2109761 reduce migration of HCC cells 
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and blocks invasion of HCC cells into the tissue microenvironment and blood vessels. 
LY2109761 also is effective in blocking tumor growth in a HCC xenograft chick embryo 
model and this antitumor activity was associated with anti-angiogenic effect (Mazzocca et 
al., 2009).  
Hepatocyte growth factor (HGF) is a cytokine secreted by mesenchymal cells. It can 
stimulate mitogenesis, cell motility and has been implicated in tumor invasion. HGF is 
secreted as a single inactive polypeptide and is cleaved by serine proteases into a 69-kDa 
alpha-chain and 34-kDa beta-chain (Matsumoto and Nakamura, 1996). Active HGF is a 
herterodimer between alpha-chain and beta-chain linked by disulfide bond. HGF is 
homologous to the plasminogen subfamily of S1 peptidases but has no detectable protease 
activity. The proto oncogene c-Met is a  receptor for HGF that is a heterodimer composed of 
a 50-kDa alpha-chain and a membrane spanning 145-kDa beta-chain with tyrosine kinase 
activity (Matsumoto and Nakamura, 1996). Activation of c-Met by HGF has been shown to 
activate MAPK, PI3K and Wnt signaling (Whittaker et al., 2010; Apte et al., 2006). 
Overexpression of c-Met was noted in 20-48% HCC tissues compared to surrounding non-
cancerous liver tissues, and the overexpression levels correlated with worsening behavior of 
HCC and decreased 5-year survival in HCC patients (Whittaker et al., 2010; Ueki et al., 
1997). A preclinical study reported that inhibition of c-Met by small molecule inhibitor 
SU11274 decreased HCC cell growth (Inagaki et al., 2011). 
3. Conclusion 
Many critical signaling pathways have been indicated in HCC development and a 
considerable amount of crosstalk and redundancy among those pathways have been 
observed. Various strategies targeting these pathways have been explored and have shown 
varying degrees of success in the clinic. Additional novel strategies are being investigated 
and raise the hope that more effective therapies may be on the horizon. However, HCC is a 
complex disease and aberrations in signaling pathways can vary from patient to patient. In 
addition, defects in multiple pathways may also in combination contribute to the 
pathogenesis. Uncovering the specific signaling pathways defects in the individual patient 
and the potential use of combination therapies may be critical for generating effective 
treatment outcomes in the future.  
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